High efficacy of finafloxacin on Helicobacter pylori isolates at pH 5.0 compared with that of other fluoroquinolones

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7629-7636

  Lee, Jung Won ^a,b   Kim, Nayoung ^a,b   Nam, Ryoung Hee ^a   Kim, Jung Mogg ^c   Park, Jong Youn ^d   Lee, Sun Min ^a   Kim, Joo Sung ^b   Lee, Dong Ho ^a,b   Jung, Hyun Chae ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Hanyang University   (South Korea)

^d MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; RNA 23S; VIRUS RNA; ANTIINFECTIVE AGENT; ASPARAGINE; ASPARTIC ACID; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLONE DERIVATIVE;

ADULT; AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG EFFICACY; FEMALE; GYRA GENE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PH; POINT MUTATION; PRIORITY JOURNAL; AMINO ACID SUBSTITUTION; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; ASPARAGINE; ASPARTIC ACID; DNA GYRASE; FEMALE; FLUOROQUINOLONES; GENE EXPRESSION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POINT MUTATION; TREATMENT OUTCOME;

EID: 84954508894     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01467-15     Document Type: Article

References (33)

1. Mentis A, Lehours P, Mégraud F. 2015. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 20(Suppl 1):1-7. http://dx.doi.org/10.1111/hel.12250.
2. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. 2012. Management of Helicobacter pylori infection - the Maastricht IV/Florence consensus report. Gut 61:646-664. http://dx.doi.org/10.1136/gutjnl-2012-302084.
3. Vakil N. 2009. H. pylori treatment: new wine in old bottles? Am J Gastroenterol 104:26-30. http://dx.doi.org/10.1038/ajg.2008.91.
4. Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. 2014. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol 29:1371-1386. http://dx.doi.org/10.1111/jgh.12607.
5. Graham DY, Fischbach L. 2010. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59:1143-1153. http://dx.doi.org/10.1136/gut.2009.192757.
6. Choi HS, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, Ryu HS. 2012. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 18:2377-2382. http://dx.doi.org/10.3748/wjg.v18.i19.2377.
7. Yoon K, Kim N, Nam RH, Suh JH, Lee S, Kim JM, Lee JY, Kwon YH, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH. 2015. The ultimate eradication rate of H. pylori after 1st, 2nd or 3rd line therapy in Korea. J Gastroenterol Hepatol 30:490-495. http://dx.doi.org/10.1111/jgh.12839.
8. Fischbach L, Evans EL. 2007. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 26:343-357. http://dx.doi.org/10.1111/j.1365-2036.2007.03386.x.
9. Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. 2013. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 18:206-214. http://dx.doi.org/10.1111/hel.12031.
10. Lee JW, Kim N, Nam RH, Park JH, Kim JM, Jung HC, Song IS. 2011. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea. Helicobacter 16:301-310. http://dx.doi.org/10.1111/j.1523-5378.2011.00840.x.
11. Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M, Mitani T, Morita Y, Tamura T, Kinoshita S, Okano Y, Kumagai S, Kasuga M. 2006. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 11:243-249. http://dx.doi.org/10.1111/j.1523-5378.2006.00415.x.
12. Rimbara E, Noguchi N, Kawai T, Sasatsu M. 2012. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. Helicobacter 17:36-42. http://dx.doi.org/10.1111/j.1523-5378.2011.00912.x.
13. Higgins PG, Stubbings W, Wisplinghoff H, Seifert H. 2010. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and-resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother 54:1613-1615. http://dx.doi.org/10.1128/AAC.01637-09.
14. Idelevich EA, Kriegeskorte A, Stubbings W, Kahl BC, Peters G, Becker K. 2011. Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes. J Antimicrob Chemother 66:2809-2813. http://dx.doi.org/10.1093/jac/dkr393.
15. Stubbings W, Leow P, Yong GC, Goh F, Korber-Irrgang B, Kresken M, Endermann R, Labischinski H. 2011. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother 55:4394-4397. http: //dx.doi.org/10.1128/AAC.00833-10.
16. Emrich NC, Heisig A, Stubbings W, Labischinski H, Heisig P. 2010. Antibacterial activity of finafloxacin under differentpHconditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance. J Antimicrob Chemother 65: 2530-2533. http://dx.doi.org/10.1093/jac/dkq375.
17. Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H, Shin CM, Park YS, Lee DH, Jung HC. 2014. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 59:1235-1243. http://dx.doi.org/10.1007/s10620-014-3093-7.
18. Kim SE, Park YS, Kim N, Kim MS, Jo HJ, Shin CM, Lee SH, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC. 2013. Effect of Helicobacter pylori eradication on functional dyspepsia. J Neurogastroenterol Motil 19:233-243. http://dx.doi.org/10.5056/jnm.2013.19.2.233.
19. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. 2006. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 28:6-13. http://dx.doi.org/10.1016/j.ijantimicag.2006.02.015.
20. Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. 2009. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 24:1230-1235. http://dx.doi.org/10.1111/j.1440-1746.2009.05829.x.
21. Hwang TJ, Kim N, Kim HB, Lee BH, Nam RH, Park JH, Lee MK, Park YS, Lee DH, Jung HC, Song IS. 2010. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol 44:536-543.
22. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. 2006. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 6:699-709. http://dx.doi.org/10.1016 /S1473-3099(06)70627-2.
23. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. 2003. Single and double mutations in gyrA but not in gyrB are associated with low-and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 47:3942-3944. http://dx.doi.org/10.1128/AAC.47.12.3942-3944.2003.
24. Graham DY, Lee YC, Wu MS. 2014. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 12:177-186. e173; discussion e112-e173. http://dx.doi.org/10.1016/j.cgh.2013.05.028.
25. Lee JW, Kim N, Kim JM, Nam RH, Kim JY, Lee JY, Lee DH, Jung HC. 2014. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. Scand J Gastroenterol 49:917-924. http://dx.doi.org/10.3109/00365521.2014.896409.
26. Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, Pilloni PA, Rocco A, Ricciardiello L, Marmo R, Loguercio C, Romano M. 2012. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 143:55-61. e51; quiz e13-e54. http://dx.doi.org/10.1053/j.gastro.2012.03.043.
27. Chang WL, Kao CY, Wu CT, Huang AH, Wu JJ, Yang HB, Cheng HC, Sheu BS. 2012. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan. Helicobacter 17:210-215. http: //dx.doi.org/10.1111/j.1523-5378.2012.00935.x.
28. Suzuki H, Nishizawa T, Muraoka H, Hibi T. 2009. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother 53:1720-1721. http: //dx.doi.org/10.1128/AAC.00049-09.
29. Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K. 2014. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol 29:487-493. http://dx.doi.org/10.1111/jgh.12442.
30. Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS. 2009. Moxifloxacin-containing triple therapy as secondline treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 14: 77-85.
31. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC. 1997. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388:539-547. http://dx.doi.org/10.1038/41483.
32. Hirata K, Suzuki H, Nishizawa T, Tsugawa H, Muraoka H, Saito Y, Matsuzaki J, Hibi T. 2010. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J Gastroenterol Hepatol 25(Suppl 1):S75-S79. http://dx.doi.org/10.1111/j.1440-1746.2009.06220.x.
33. Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. 2010. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol 16:1279-1284. http://dx.doi.org/10.3748/wjg.v16.i10.1279.